Our technology
The premier full-spectrum product platform
Growing body of microbiota transfer studies report transformational outcomes for patients
Intestinal microbiota transfer (IMT)
The transfer of microbiome communities from a healthy person into the intestinal tract of another person suffering from a microbiome mediated disease
IMT is the most powerful means to enhance the microbiome
The number of IMT clinical trials has increased dramatically since 2010
Traditional intestinal microbiome transplant products
Liquid suspensions, brown colour with odour
Stored frozen at -80 degrees celsius
Variable donor dependent composition
Variable safety screening under non-GMP controls
Non scalable processes
Administered through invasive procedures
Image credit: F Gandolfo MD
EnteroBiotix has developed the premier approach to intestinal microbiota transfer
We’ve established full control over the supply chain
The premier platform
Premier full-spectrum medicines
CASE STUDY 01
IMT in liver disease
Increasing diversity through intestinal microbiota transfer improves liver disease and hepatic encephalopathy
CASE STUDY 02
Microbiome diversity impacts cancer patient outcomes
Intestinal microbiota transfer improves outcomes in cancer patients
Higher overall survival in allo-HSCT patients receiving IMT
Innes, Mullish, Ghani et al. Front Cell Infect Micro (2021)
Malignant Melanoma
Baruch Science 2021; Davar Science 2021; Miller J Clin Oncol 2022 (ASCO abstract)